GlassScriptPhysician profile
Anna Y Rybka
NPI 1386968360
$2,795.62
in general payments reported to CMS, 2019-2025
37 companies · $517 in 2025
The $517 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $132 · 2021: $246 · 2022: $695 · 2023: $511 · 2024: $221 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.83 | 2019-2023 | Lo Loestrin Fe |
| Aspira Women'S Health INC | $316.21 | 2022-2024 | Ova1 |
| Astellas Pharma US INC | $236.23 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $184.26 | 2022-2025 | |
| Hologic Sales and Service, LLC | $180.30 | 2022-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Therapeuticsmd, INC. | $132.31 | 2019-2022 | |
| Organon LLC | $105.06 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $104.44 | 2019-2025 | Slynd, Twirla |
| Evofem Biosciences, INC. | $98.65 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $90.01 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $84.72 | 2019-2024 | |
| Radius Health, INC. | $73.85 | 2019-2023 | Tymlos |
| Pfizer INC. | $68.76 | 2021-2022 | |
| Avion Pharmaceuticals | $57.88 | 2020-2022 | |
| Channel Medsystems, INC. | $54.19 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.96 | 2019 | |
| Ethicon US, LLC | $49.49 | 2023 | Dermabond, Dermabond Prineo, Vistaseal |
| Daiichi Sankyo INC. | $46.40 | 2019-2021 | |
| Duchesnay USA Incorporated | $44.89 | 2019 | |
| Agile Therapeutics, INC. | $43.50 | 2021-2023 | Twirla |
| Scynexis, INC. | $41.95 | 2022 | |
| Becton, Dickinson and Company | $41.76 | 2025 | Arista |
| Coopersurgical, INC. | $31.32 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $30.08 | 2022 | |
| Minerva Surgical, INC | $29.36 | 2025 | |
| Avanos Medical | $29.34 | 2019 | |
| Millicent US INC | $22.52 | 2025 | Femlyv |
| Seqirus USA INC | $21.74 | 2025 | Flucelvax |
| Biogen, INC. | $19.54 | 2025 | Zurzuvae |
| Meditrina | $19.23 | 2024-2025 | |
| Baxter Healthcare | $18.20 | 2025 | Perclot |
| Vertical Pharmaceuticals, LLC | $17.20 | 2019 | |
| Exact Sciences Corporation | $16.26 | 2023 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $15.16 | 2025 | Pico 14 |
| Amag Pharmaceuticals, INC. | $14.96 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.63 | 2024 | Caldolor |
| Lilly USA, LLC | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Rybka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.